IGC Pharma Inc (IGC)

Currency in USD
0.1680
-0.0160(-8.70%)
Closed·
0.1701+0.0021(+1.25%)
·
IGC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.16800.1863
52 wk Range
0.08000.3600
Key Statistics
Prev. Close
0.168
Open
0.1832
Day's Range
0.168-0.1863
52 wk Range
0.08-0.36
Volume
514.21K
Average Volume (3m)
636K
1-Year Change
-46.6667%
Book Value / Share
0.067
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IGC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.2500
Upside
+3,620.24%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

IGC Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.2500
(+3,620.24% Upside)

IGC Pharma Inc Earnings Call Summary for Q2/2026

  • IGC Pharma renewed a $12M line of credit and divested a non-core facility, resulting in $1.1M non-cash profit and $600K annual expense reduction
  • The company reported progress in its CALMA phase two Alzheimer's trial with expanded patient enrollment across U.S. and Canada sites
  • Stock rose 2.74% in pre-market trading to $0.3678, showing investor optimism despite a previous 2.07% decline
  • CEO Ram Mukunda forecasts completion of CALMA phase two trial by first half of 2027, emphasizing potential for early symptom reduction
  • Company faces challenges with negative EPS forecasts but maintains focus on its MINT-AD AI platform for early Alzheimer's risk assessment
Last Updated: 2025-11-17, 11:58 a/m
Read Full Transcript

Earnings

Latest Release
Nov 09, 2026
EPS / Forecast
-0.02 / -0.02
Revenue / Forecast
328K / 96K
EPS Revisions
Last 90 days

IGC Income Statement

Compare IGC to Peers and Sector

Metrics to compare
IGC
Peers
Sector
Relationship
P/E Ratio
−3.0x11.5x−0.2x
PEG Ratio
−0.05−0.340.00
Price/Book
3.2x2.1x2.6x
Price / LTM Sales
17.7x1.8x2.6x
Upside (Analyst Target)
-76.0%77.0%
Fair Value Upside
Unlock35.4%13.7%Unlock

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.90M2.49%487.24K
Other Institutional Investors
21.62M18.53%3.63M
Public Companies & Retail Investors
92.17M78.99%15.48M
Total
116.69M100.00%19.6M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bradbury Fund Management Limited15.10%17,623,5292,961
Vanguard Capital Management, LLC1.11%1,290,127217

People Also Watch

51.79
APPN
+1.61%
0.0140
DVLT
-29.65%
2.0600
CRBP
-15.40%
0.1650
SOAR
-12.23%

FAQ

What Is the IGC Pharma (IGC) Stock Price Today?

The IGC Pharma stock price today is 0.1680 USD.

What Stock Exchange Does IGC Pharma Trade On?

IGC Pharma is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for IGC Pharma?

The stock symbol for IGC Pharma is "IGC."

What Is the IGC Pharma Market Cap?

As of today, IGC Pharma market cap is 19.6000M USD.

What Is IGC Pharma's Earnings Per Share (TTM)?

The IGC Pharma EPS (TTM) is -0.078.

When Is the Next IGC Pharma Earnings Date?

IGC Pharma will release its next earnings report on Mar 03, 2027.

From a Technical Analysis Perspective, Is IGC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IGC Pharma Stock Split?

IGC Pharma has split 1 times.

How Many Employees Does IGC Pharma Have?

IGC Pharma has 70 employees.

What is the current trading status of IGC Pharma (IGC)?

As of Nov 22, 2026, IGC Pharma (IGC) is trading at a price of 0.1680 USD, with a previous close of 0.1680 USD. The stock has fluctuated within a day range of 0.1680 USD to 0.1863 USD, while its 52-week range spans from 0.0800 USD to 0.3600 USD.

What Is IGC Pharma (IGC) Price Target According to Analysts?

The average 12-month price target for IGC Pharma is 6.2500 USD, with a high estimate of 6.25 USD and a low estimate of 6.25 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +3,620.24% Upside potential.

What Is the IGC Premarket Price?

IGC's last pre-market stock price is 0.1951 USD. The pre-market share volume is 3,500.0000, and the stock has decreased by 0.0111, or 6.0300%.

What Is the IGC After Hours Price?

IGC's last after hours stock price is 0.1701 USD, the stock has decreased by 0.0021, or 1.2500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.